Cargando…

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review

The accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing antibody-based therapeutics is a concern with potentially severe implications for public health. We review here reports of documented immune escape after treatment with monoclonal antibodies and COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Maggi, Fabrizio, Franchini, Massimo, McConnell, Scott, Casadevall, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744556/ https://www.ncbi.nlm.nih.gov/pubmed/35008446 http://dx.doi.org/10.3390/ijms23010029

Ejemplares similares

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
por: Focosi, Daniele, et al.
Publicado: (2023)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
por: Focosi, Daniele, et al.
Publicado: (2021)

Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?
por: Focosi, Daniele, et al.
Publicado: (2022)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID19 immune plasma donation after vaccination: pros and cons.
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons
por: Casadevall, Arturo
Publicado: (2002)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

TTV viral load as a predictor of antibody response to SARS COV-2 vaccination
por: Focosi, Daniele, et al.
Publicado: (2023)

What a Transfusion Physician Should Know about Monkeypox Virus: Barriers to and Risks for Transmission, and Possible Mitigation Strategies
por: Focosi, Daniele, et al.
Publicado: (2022)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ull3vnmqn2mn1665eivnp95nbb